AbbVie 2012 Annual Report Download - page 146

These amounts include Abbott contributions to both the Abbott tax-qualified defined contribution
plan and the Abbott Laboratories 401(k) Supplemental Plan. The Abbott Laboratories 401(k)
Supplemental Plan permits the named executive officers to contribute amounts in excess of the
annual limit set by the Internal Revenue Code for employee contributions to 401(k) plans up to
the excess of (i) 18 percent of their base salary over (ii) the amount contributed to Abbott’s
tax-qualified 401(k) plan. Abbott matches participant contributions at the rate of 250 percent of
the first 2 percent of compensation contributed to the plan. The named executive officers have
these amounts paid to them in cash on a current basis and deposited into a grantor trust
established by the officer, net of maximum tax withholdings.
Other Compensation
The following amounts are included in the totals in this column, which reflect Abbott’s incremental
cost less reimbursements for non-business related flights: Mr. Gonzalez: $294,607 / $372,823 /
$185,808.
Abbott determines the incremental cost for flights based on the direct cost to Abbott, including
fuel costs, parking, handling and landing fees, catering, travel fees, and other miscellaneous direct
costs.
Also included in the totals shown in the table is the cost of providing a corporate automobile less
the amount reimbursed by the officer: L. J. Schumacher: $16,876 / $18,802 / $21,164; W. J. Chase:
$5,716 / $13,026; C. Alban: $17,760 / $17,300; and J. M. Leonard: $18,321 / $18,772.
For Ms. Schumacher, Messrs. Chase and Alban, and Dr. Leonard, the following costs associated
with financial planning are included: L. J. Schumacher: $0 / $10,000 / $10,000;
W. J. Chase: $6,500 / $6,500; C. Alban: $10,000 / $11,447; and J. M. Leonard: $8,000 / $8,000.
For Mr. Alban, the totals include $3,063 in 2012 and $13,314 in 2011 for relocation costs.
The named executive officers are also eligible to participate in an executive disability benefit
described in the section of this proxy captioned ‘‘Potential Payments Upon Termination—
Generally.’’
(7) Bonus paid to Mr. Gonzalez in 2010 upon his appointment as Executive Vice President,
Pharmaceutical Products Group.
(8) Bonus paid in recognition of performance related to the business separation.
2012 GRANTS OF PLAN-BASED AWARDS
All Other
Estimated Future Estimated Option
Payouts Under Future Awards: Exercise Grant Date
Non-Equity Payouts Numbers of or Base Closing Fair Value
Incentive Plan Under Equity Securities Price of Market of Stock
Awards(1) Incentive Underlying Options Price on and
Grant Target Maximum Plan Awards Options Awards Grant Option
Name Date ($) ($) Target (#) (#) ($/Sh.) Date Awards
R. A. Gonzalez ...... 02/17/12 59,400(2)(3) $3,341,844(4)
02/17/12 107,300(5) $56.26 $56.36 729,640(6)
L. J. Schumacher ..... 02/17/12 44,200(2)(3) 2,486,692(4)
12/01/12 30,755(7) 1,999,998(4)
02/17/12 79,800(5) 56.26 56.36 542,640(6)
06/18/12 3,611(8) 62.50 62.70 6,897(6)
06/19/12 165(8) 62.70 62.87 317(6)
06/19/12 6,408(8) 62.70 62.87 15,443(6)
07/30/12 4,011(8) 66.39 66.60 11,512(6)
32